The Pharmacy Times® Hematology Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of blood disorders, including blood and bone marrow cancers, leukemia, and myeloma.
July 31st 2025
Sanofi's SAR446523 receives orphan drug designation for relapsed refractory multiple myeloma, enhancing treatment options and patient outcomes.
EHA 2025: No Added Toxicity Observed With Bleximenib Plus Venetoclax and Azacitidine in AML
July 22nd 2025Andrew H. Wei, PhD, discusses phase 1b findings on the safety, pharmacokinetics, and preliminary efficacy of combining the menin inhibitor bleximenib with venetoclax and azacitidine in patients with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) harboring NPM1 mutations or KMT2A rearrangements.
Read More
FDA Panel Rejects Belantamab Mafodotin Combinations for Multiple Myeloma, Citing Safety Concerns
July 18th 2025The advisory committee cited concerns around ocular toxicity and overall tolerability, raising serious questions about the drug's benefit-risk profile ahead of its scheduled Prescription Drug User Fee Act action date on July 23, 2025.
Read More
NCCN Flash Update: Updated CML Guidelines Emphasize Distress Screening, Drug Interactions, and Cost
July 18th 2025The updated version 1.2026 NCCN Guidelines for chronic myeloid leukemia (CML) emphasize individualized treatment strategies, TKI-specific considerations, drug interaction management, and pregnancy safety, highlighting the critical role of oncology pharmacists in optimizing therapy selection, patient counseling, and cost-effective care.
Read More
This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.
Read More
ASCO 2025: Asciminib Demonstrates Superiority Compared With Nilotinib in Ph+ CML-CP
June 11th 2025Asciminib shows superior tolerability over nilotinib in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase, enhancing treatment options and patient outcomes.
Read More